Literature DB >> 12429734

Cisplatin sensitivity in Hmbg1-/- and Hmbg1+/+ mouse cells.

Min Wei1, Olga Burenkova, Stephen J Lippard.   

Abstract

The study presented here investigates the effect of HMGB1 knockout on the sensitivity of mouse embryonic fibroblasts treated with the anticancer drug cisplatin. We evaluated both the growth inhibition by cisplatin and cisplatin-induced cell death in the Hmgb1(-/-) cells and its wild-type counterpart. No significant differences were observed in the responses of these cells to cisplatin, indicating that HMGB1 does not play a significant role in modulating the cellular responses to cisplatin in this context. Since HMGB1 significantly enhances the cytotoxicity of cisplatin in other cells, these results illustrate the importance of cell type in determining the ability of this and probably other cisplatin-DNA-binding proteins to influence the efficacy of the drug.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429734     DOI: 10.1074/jbc.M210562200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

Review 1.  The role of chromatin proteins in DNA damage recognition and repair.

Authors:  Piotr Widlak; Monika Pietrowska; Joanna Lanuszewska
Journal:  Histochem Cell Biol       Date:  2006-01       Impact factor: 4.304

2.  Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair.

Authors:  Hana Kostrhunova; Jaroslav Malina; Amanda J Pickard; Jana Stepankova; Marie Vojtiskova; Jana Kasparkova; Tereza Muchova; Matthew L Rohlfing; Ulrich Bierbach; Viktor Brabec
Journal:  Mol Pharm       Date:  2011-08-17       Impact factor: 4.939

3.  Redox state-dependent interaction of HMGB1 and cisplatin-modified DNA.

Authors:  Semi Park; Stephen J Lippard
Journal:  Biochemistry       Date:  2011-02-28       Impact factor: 3.162

4.  High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs.

Authors:  Natalia Krynetskaia; Hongbo Xie; Slobodan Vucetic; Zoran Obradovic; Evgeny Krynetskiy
Journal:  Mol Pharmacol       Date:  2007-10-19       Impact factor: 4.436

Review 5.  Interactions of high mobility group box protein 1 (HMGB1) with nucleic acids: Implications in DNA repair and immune responses.

Authors:  Pooja Mandke; Karen M Vasquez
Journal:  DNA Repair (Amst)       Date:  2019-09-16

6.  Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage.

Authors:  Natalia F Krynetskaia; Manali S Phadke; Sachin H Jadhav; Evgeny Y Krynetskiy
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

Review 7.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

8.  DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexes.

Authors:  Olga Novakova; Jana Kasparkova; Jaroslav Malina; Giovanni Natile; Viktor Brabec
Journal:  Nucleic Acids Res       Date:  2003-11-15       Impact factor: 16.971

9.  Monofunctional and higher-valent platinum anticancer agents.

Authors:  Timothy C Johnstone; Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2013-06-05       Impact factor: 5.165

10.  HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic.

Authors:  Sabine S Lange; Karen M Vasquez
Journal:  Mol Carcinog       Date:  2009-07       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.